Cardiovascular Business July 15, 2024
Edwards Lifesciences has agreed to acquire Innovalve Bio Medical, an Israel-based medical device company focused on structural heart disease technologies. Financial terms of the deal have not been announced to the public.
Edwards had an open option to acquire Innovalve after initially investing in the company back in 2017. It chose to exercise that option after Innovalve “demonstrated progress” with “promising” early results.
Innovalve’s primary focus is its new Innostay transcatheter mitral valve replacement (TMVR) system, a minimally-invasive device designed to treat patients with severe mitral regurgitation (MR). The Innostay TMVR system rotates in a way that produces “robust anchoring and excellent sealing.” According to Innovalve, it can be deployed quickly, leading to short procedure times, and was built to...
Today's Sponsors
Today's Sponsor